Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.62 |
| ▸ | DRD4 | P21917 | 7/20 | 0.58 |
| ▸ | DRD3 | P35462 | 7/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD5 | P21918 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 1/20 | 0.58 |
| ▸ | HTR1E | P28566 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | GPR183 | P32249 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094010 | 1.00 | DRD2 (0.62) | DRD2DRD4DRD3HTR1ADRD1 | |
| Hydrochloric Acid SCHEMBL18496124 | 0.99 | DRD2 (0.61) | DRD2DRD4DRD3HTR1ADRD1 | |
| Hydrochloric Acid SCHEMBL29922934 | 0.99 | DRD2 (0.61) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL20029449 | 0.92 | DRD2 (0.71) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL30193630 | 0.90 | DRD2 (0.66) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL30193881 | 0.88 | DRD2 (0.66) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL30193634 | 0.88 | HRH3 (0.64) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL30193620 | 0.86 | DRD2 (0.63) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL18507816 | 0.86 | DRD2 (0.64) | DRD2DRD4DRD3HTR1ADRD1 | |
| SCHEMBL30193406 | 0.85 | DRD2 (0.64) | DRD2DRD4DRD3HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018087775-A1 | PROCESSES FOR THE PREPARATION OF 7-{4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY}QUINOLIN-2(1H)-ONE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-17 | — | — | WO | claimed |
| WO-2022078306-A1 | LARGE STERIC HINDERANCE PALLADIUM-NITROGEN-HETEROCYCLIC CARBENE COMPLEX, PREPARATION METHOD FOR SAME, APPLICATIONS OF SAME, AND SYNTHESIS METHOD FOR SONIDEGIB BASED ON SAME | 中山大学 | 2022-04-21 | — | — | WO | disclosed |
| US-11279696-B2 | Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one | MSN LABORATORIES PRIVATE LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| WO-2019073481-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND ITS INTERMEDIATES | INDOCO REMEDIES LIMITED (IN) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018172463-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018087775-A1 | PROCESSES FOR THE PREPARATION OF 7-{4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY}QUINOLIN-2(1H)-ONE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087775-A1 | PROCESSES FOR THE PREPARATION OF 7-{4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY}QUINOLIN-2(1H)-ONE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018060916-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017216661-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE FROM 7-(4-CHLOROBUTOXY)QUINOLIN-2(1H)-ONE AND 1-(BENZO[B]THIOPHEN-4-YL)PIPERAZINE | Jubilant Generics Limited (IN) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017025987-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE | MYLAN LABORATORIES LIMITED (IN) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025987-A1 | PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE | MYLAN LABORATORIES LIMITED (IN) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279696-B2 | Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one | CYP1B1, CYP4B1, CYP1A1 | DRD2 3347/4885DRD4 1808/4885DRD3 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.